Editorial: Closing in on the Role of Thymic Stromal Lymphopoietin Inhibition as a Therapeutic Entry Point for Systemic Sclerosis

Research output: Contribution to journal › Article › Academic

Cite this

@article{67e0c150858b46218306396676bfae34,

title = "Editorial: Closing in on the Role of Thymic Stromal Lymphopoietin Inhibition as a Therapeutic Entry Point for Systemic Sclerosis",

keywords = "Cytokines, Humans, Receptors, Cytokine, Scleroderma, Systemic",

author = "Affandi, {Alsya J} and {van Roon}, {Joel A G}",

year = "2016",

month = "11",

doi = "10.1002/art.39815",

language = "English",

volume = "68",

pages = "2571--2574",

journal = "Arthritis & rheumatology",

issn = "2326-5191",

publisher = "John Wiley and Sons Ltd",

number = "11",

}

TY - JOUR

T1 - Editorial

T2 - Closing in on the Role of Thymic Stromal Lymphopoietin Inhibition as a Therapeutic Entry Point for Systemic Sclerosis

AU - Affandi, Alsya J

AU - van Roon, Joel A G

PY - 2016/11

Y1 - 2016/11

KW - Cytokines

KW - Humans

KW - Receptors, Cytokine

KW - Scleroderma, Systemic

U2 - 10.1002/art.39815

DO - 10.1002/art.39815

M3 - Article

C2 - 27428811

VL - 68

SP - 2571

EP - 2574

JO - Arthritis & rheumatology

JF - Arthritis & rheumatology

SN - 2326-5191

IS - 11

ER -